Strategic report Corporate governance Financial statements Financial statements Notes to the consolidated financial statements continued 16.
Investments in associates and joint ventures 17.
Deferred tax continued The Groups share in Hubei Haosun Pharmaceutical Co Ltd China is 30.1% at 31 December 2016 31 December 2015: 30.1% with an The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and investment balance of $4 million at 31 December 2016 31 December 2015: $4 million, prior reporting years.
The Groups share of the results of Hubei Haosun Pharmaceutical Co. Ltd is $nil 2015: share of the results of Unimark Remedies Limited Other shortand Hubei Haosun Pharmaceutical Co Ltd is a loss of $2million.
term Deferred R&D temporary Amortisable Share-based In previous periods, the Group impaired the remaining investment balance related to Unimark Remedies Limited of $7 million which was Tax losses costs differences assets Fixed assets payments Total due to the continuous financial difficulties.
Hikmas share in Unimark Remedies Limited has been divested during 2016 for minimal value.
$m $m $m $m $m $m $m At 1 January 2015 4 1 77 20 22 2 42 The below represents the Groups share of the result of Hikma Cure and Hubei Haosun Pharmaceutical Co Ltd. which is included in the Credit Charge to income 1 3 1 6 5 consolidated income statement.
Charge to equity 1 1 For the year ended 31 December 2016 For the year ended 31 December 2015 Remeasurement 2 2 Joint Joint Exchange differences 1 1 1 1 ventures Associates Total ventures Associates Total $m $m $m $m $m $m At 1 January 2016 4 1 74 18 13 1 49 Balance at 1 January 3 4 7 3 13 16 Credit Charge to income 2 70 10 16 1 65 Share of loss 2 2 Acquisition of subsidiary note 43 61 20 2 39 Impairment of investment note 5 7 7 Exchange differences 3 5 2 4 Balance at 31 December 3 4 7 3 4 7 At 31 December 2016 6 1 202 23 29 157 Summarised financial information in respect of the Groups interests in associated companies is set out below: The other short-term temporary differences primarily relate to charge backs, product returns and unrealised intercompany profits in the US.
Further to Bedford Laboratories Bedford acquisition in 2014, a reduction of $8 million was made to the provisional goodwill recognised on the As at As at acquisition of Bedford as a result of the adjustment to inventory, property plant and equipment and deferred tax made prior to the end of the measurement 31 December 31 December period on 15 July 2015.
2016 2015 No deferred tax asset has been recognised on temporary differences totalling $189 million 2015: $164 million due to the unpredictability $m $m of the related future profit streams.
$167 million of these temporary differences relate to losses on which no deferred tax is recognised.
Total assets 15 214 None of these losses are expected to expire.
Total liabilities 5 160 Net assets 10 54 We have recognised a deferred tax liability on temporary differences relating to the unremitted earnings of overseas subsidiaries of $2 Groups share of net assets of associates 3 13 million 2015: nil.
No deferred tax liability has been recognised on the remaining unremitted earnings of $208 million 2015: $122 million, as the Group is able to control the timing of the reversal of these temporary differences and it is probable that they will not reverse in the For the For the foreseeable future.
year ended year ended 31 December 31 December 2016 2015 18.
Financial and other non-current assets $m $m As at 31 December Total revenue 4 49 2016 2015 Net loss 23 $m $m Groups share of loss of associates 2 Price adjustment receivable note 43 3 Available-for-sale investments 7 2 17.
Deferred tax Other non-current asset 38 44 Certain deferred tax assets and liabilities have been appropriately offset.
The following is the analysis of the deferred tax balances after 48 46 offset for financial reporting purposes: Price adjustment receivable represents the non-current portion of the total contingent receivable of $118 million in relation of WestAs at 31 December Ward Columbus acquisition note 30 and 43.
During the year, the Group received $82 million in cash as part of certain working capital, 2015 2016 milestones and other receivables.
$m $m Available-for-sale investments include investments of $6 million in two venture capital companies through the Groups venture capital Deferred tax liabilities 15 21 arm Hikma international ventures developments LLC.
Deferred tax assets 172 70 Other non-current assets mainly represent advance payments made to acquire both products and product related technologies from 157 49 third parties.
During the year, any payments related to product related technologies were reclassified to intangible assets while any payments related to products will be reclassified to inventory once received.
Annual Report 2016 177 168 Hikma Pharmaceuticals plc Annual Report 2016 169
